James Golubieski

Foundation Venture Capital Group LLC (Foundation Venture) is a venture capital firm headquartered in Princeton, New Jersey. Founded in 2006, the firm is the equity investment arm of New Jersey Health Foundation Inc.

Celvive, Inc. engages in the development of technology for the isolation and use of autologous cellular therapy for regenerative medicine applications. It specializes in using a closed bag system to isolate specific adult stem cells from the patients' own bone marrow. The company was founded by Hatem E. Sabaawy in 2011 and is headquartered in New Brunswick, NJ.

NovoPedics, Inc. develops implantable medical devices that restore mobility to patients suffering from severe meniscus knee injuries. It provides a way to replace damaged meniscus tissue with a patented fiber-reinforced design similar to the native meniscus and can be attached to both soft tissue and bone, allowing it to be used in total meniscus replacement surgery. The company was founded by Charles J. Gatt Jr. and Michael G. Dunn in 2013 and is headquartered in New Brunswick, NJ.

Actinobac Biomed, Inc. operates as a biopharmaceutical company developing therapeutics. It offers therapeutics for indications, including blood cancers, autoimmune, inflammatory diseases and HIV. The company was founded by Scott C. Kachlany in 2009 and is headquartered in Kendall Park, NJ.

NemaGen Discoveries, Inc. is a biotech company located in Princeton, NJ. The company focuses on developing therapies for patients with allergic inflammation and mast cell-related diseases. NemaGen's unique approach to drug development involves investigating the body's natural ability to prevent unwanted inflammation following parasitic infections. Recently, NemaGen announced its participation in the NIH I-Corps program to better understand stakeholders' needs and validate the value of its therapies. The company was founded by Mark Siracusa and has been led by CEO Nicholas Shubin since 2022.

GeneAssess, Inc. discovers, develops and commercializes novel diagnostic tests that help physicians to treat and improve outcomes for cancer patients. The firm engages in developing new diagnostic and genetic tests for assessing cancer risk based on the expression and the DNA sequence of the FRY, a putative tumor suppressor gene and a novel cancer biomarker. The company was founded by Helmut Zarbl in June 2012 and is headquartered in New Brunswick, NJ.

CellXplore, Inc. operates as a biotechnology company which engages in the development of biomarker-based in vitro diagnostic assays. The firm commercializes groundbreaking discoveries demonstrating up-regulation of the ubiquitin-proteasome pathway in cancerous breast tissue, providing the capability for the noninvasive detection of breast cancer and the ability to monitor the efficacy of chemotherapeutic interventions. The company was founded by Kiran Madura on September 24, 2007 and is headquartered in New Brunswick, NJ.

Part of KPMG International Cooperative, KPMG, Inc. provides audit and accounting services. The company is based in Vancouver, Canada. The CEO of the Canadian company is Walter R. Pela.